SCHEMBL375450

SCHEMBL375450

O=C1c2ccccc2C(=O)c2c(NCCCO)ccc(NCCCO)c21

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2B Q02880 1/20 0.71
CYP19A1 P11511 1/20 0.66
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
BLM P54132 4/20 0.64
POLB P06746 3/20 0.64
NSD2 O96028 3/20 0.64
RXFP1 Q9HBX9 1/20 0.64
LMNA P02545 5/20 0.61
MAPT P10636 5/20 0.61
ALDH1A1 P00352 5/20 0.61
HTT P42858 4/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
MAPK1 P28482 4/20 0.61
RECQL P46063 3/20 0.61
NPSR1 Q6W5P4 3/20 0.61
L3MBTL1 Q9Y468 3/20 0.61
EGFR P00533 2/20 0.61
RAD52 P43351 1/20 0.61
NPC1 O15118 3/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL455300 0.97 TOP2B (0.72) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL15271588 0.94 TOP2B (0.73) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL6661577 0.92 CYP19A1 (0.80) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL20710632 0.92 TOP2B (0.62) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL9883948 0.92 TOP2B (0.62) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL15271304 0.91 TOP2B (0.83) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL1426702 0.89 TOP2B (0.81) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL29357976 0.89 TOP2B (0.81) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL32679354 0.89 MAPT (0.77) TOP2BCYP19A1MEN1KMT2ABLM
SCHEMBL6678121 0.89 MAPT (0.77) TOP2BCYP19A1MEN1KMT2ABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504495-B2 Quencher compositions comprising anthraquinone moieties EXIQON A/S (DK) 2009-03-17 US claimed
EP-1538154-B1 Quencher composition comprising anthraquinone moieties EXIQON AS (DK) 2008-12-31 EP claimed
EP-1831394-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME Exiqon A/S (DK) 2007-09-12 EP claimed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 US claimed
WO-2006066592-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME EXIQON A/S (DK) 2006-06-29 WO claimed
EP-1039876-B1 DIRECT HAIR DYE COMPOSITIONS AND METHODS CONTAINING NOVEL ANTHRAQUINONE MIXTURES P & G CLAIROL INC (US) 2006-06-07 EP claimed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 US claimed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 EP claimed
US-20250361401-A1 REACTIVE DYES ALCON INC (CH) 2025-11-27 US disclosed
WO-2025243219-A1 REACTIVE DYES AND THEIR USE IN CONTACT LENSES ALCON INC. (CH) 2025-11-27 WO disclosed
US-20240209420-A1 COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES KASA BIO, L.L.C. 2024-06-27 US disclosed
EP-4388133-A2 COMPOSITIONS AND METHODS FOR MULTIPLEX DETECTION OF MIRNA AND OTHER POLYNUCELOTIDES Kasa Bio, L.L.C. (US) 2024-06-26 EP disclosed
US-11952617-B2 Methods for multiplex detection of polynucleotides using unbound fluorescent probes and quencher oligonucleotides KASA BIO, L.L.C. (US) 2024-04-09 US disclosed
EP-3229918-B1 COMPOSITION AND PROCEDURE FOR TREATING KERATINIC FIBERS WITH FLASH EVAPORATION HENKEL AG & CO KGAA (DE) 2024-03-13 EP disclosed
US-20060166238-A1 Probes, libraries and kits for analysis of mixtures of nucleic acids and methods for constructing the same EXIQON A/S (DK) 2006-07-27 US disclosed
WO-2006066592-A2 PROBES, LIBRARIES AND KITS FOR ANALYSIS OF MIXTURES OF NUCLEIC ACIDS AND METHODS FOR CONSTRUCTING THE SAME EXIQON A/S (DK) 2006-06-29 WO disclosed
US-20060014183-A1 Extendable probes EXIQON A/S (DK) 2006-01-19 US disclosed
US-20050272075-A1 Novel methods for quantification of microRNAs and small interfering RNAs QIAGEN GMBH (DE) 2005-12-08 US disclosed
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties QIAGEN GMBH (DE) 2005-10-13 US disclosed
EP-1538154-A1 Quencher composition comprising anthraquinone moieties Exiqon A/S (DK) 2005-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227254-A1 Quencher compositions comprising anthraquinone moieties ANXA5, SUN2, ANXA3 TOP2B 1504/4885CYP19A1 4281/4885MEN1 3235/4885
US-20060014183-A1 Extendable probes POLRMT, RNGTT, POLL TOP2B 438/4885CYP19A1 2565/4885MEN1 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.